Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitstry vs RxSpan MD

Fitstry
Graded #300

Lower grade

vs+25.599999999999994
RxSpan MD
Graded #4

Higher grade

The verdict

RxSpan MD takes it — 86.8/100 to 61.2/100.

RxSpan MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A physician-led telehealth under board-certified founder Dr. John Diaz with a broad GLP-1 menu — compounded semaglutide and tirzepatide by injection or oral capsule, plus a brand-name lane and microdosing — on transparent all-inclusive pricing to all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRxSpan MD +57
29
86
Dose & formulationRxSpan MD +14
75
89
Clinical oversightRxSpan MD +7
81
88
Labs & monitoringRxSpan MD +10
73
83
FulfillmentRxSpan MD +22
67
89
Contract termsRxSpan MD +38
47
85
Fitstry · left barRxSpan MD · right bar

The numbers

MetricFitstryRxSpan MD
WeighScore61.2/10086.8/100
GradeCB
Scorecard rank#300#4
Semaglutide$179/mo (annual plan, plus a separate fee, compounded)From $194/mo
Tirzepatide$269/mo (annual plan, compounded)$329/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Fitstry

Graded #300 · C

Strengths

  • Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
  • Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
  • Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
  • Runs under Weightstry, LLC, a LegitScript-certified practice with an independently verifiable seal, a named support email and phone
  • Full compounded lineup — weekly injection, daily oral tablet and microdosing options

Where it loses points

  • Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
  • Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
RxSpan MD

Graded #4 · B

Strengths

  • Available in all 50 states
  • Transparent, all-inclusive published pricing — consult, medication, supplies, shipping and support, cancel anytime, from ~$194/mo compounded semaglutide on an annual plan
  • Both injectable and a real oral (capsule) route, plus compounded and an advertised brand-name lane
  • Physician-led by a named, board-certified founder (Dr. John Diaz) with 24/7 messaging and coaching

Where it loses points

  • Compounded semaglutide/tirzepatide are not FDA-approved (not the same as Wegovy/Ozempic/Zepbound)
  • Published pricing is for the compounded line — brand-name pricing isn’t itemized
  • A prescription isn’t guaranteed — a provider reviews eligibility after checkout

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard